There's more than one player in the mRNA COVID-19 vaccine race.
News & Analysis: BioNTech SE
BNTX earnings call for the period ending March 31, 2020.
Size may matter in the long run.
The big pharma giant will outsource the production of medicines it sells now for a chance to halt the virus responsible for COVID-19 in its tracks.
Clinical trials of their experimental vaccine to prevent COVID-19 started in Germany last month.
Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.
Shares simply cooled off from an impressive run-up through March, but investors are still closely watching this biotech stock.
They're off to a fast start, but the companies still have a long ways to go.
Pfizer Gets German Approval To Start COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works.
Pfizer is developing a potential coronavirus treatment and a vaccine candidate. With potential big wins in the near future, is now the time to buy?
Pfizer's European biotech partner will soon begin early-stage testing of four experimental SARS-CoV-2 vaccines.